CPXM2 Antibody

What is CPXM2 and why is it important in medical research?

CPXM2 is a member of the carboxypeptidase X, M14 family that has been associated with several human disorders. Initially linked to developmental diseases , late-onset Alzheimer's disease, and cognitive decline in schizophrenia , recent research has demonstrated its significance in oncological contexts. Studies have shown CPXM2 overexpression in gastric cancer and osteosarcoma with associations to unfavorable prognosis and tumor progression .

The protein appears to play an active role in promoting tumor aggressiveness by modulating epithelial-mesenchymal transition (EMT) . This makes CPXM2 not only a potential biomarker for disease progression but also a promising therapeutic target, driving the need for reliable antibodies for detection and functional studies.

What are the optimal Western blot conditions for detecting CPXM2 protein?

Based on validated protocols, researchers should consider the following conditions for optimal CPXM2 detection in Western blot applications:

• Sample preparation: Total protein extraction using RIPA lysis buffer containing protease inhibitors is recommended for cell cultures or tissue homogenates

• Protein loading: 30 μg of protein is sufficient for detection in most samples

• Gel percentage: 10% SDS-PAGE provides adequate separation

• Primary antibody dilution: 1:500-1:1000 range (1:500 for overnight incubation at 4°C has been validated)

• Blocking solution: 5% milk powder in TBST buffer

• Secondary antibody: HRP-conjugated, used at 1:2000-1:5000 dilution for 1 hour at room temperature

• Detection system: Enhanced chemiluminescence (ECL) with 5-10 minutes exposure

• Expected molecular weight: The CPXM2 protein band appears at approximately 86-90 kDa

Note that multiple bands may appear, so proper controls and validation are essential for accurate interpretation.

How should immunohistochemistry protocols be optimized for CPXM2 detection in tissue sections?

For effective immunohistochemical detection of CPXM2 in tissue sections, follow these validated methodological steps:

• Deparaffinization and rehydration: Process slides through xylene and graded ethanol series

• Antigen retrieval: Use citrate buffer pH 6.0 (1:300 dilution)

• Blocking: Apply appropriate blocking solution to reduce non-specific binding

• Primary antibody: Use rabbit anti-CPXM2 polyclonal antibody at 1:50 dilution (for gastric cancer tissues) or 1:250 dilution (for osteosarcoma tissues) with overnight incubation at 4°C

• Secondary antibody: Apply HRP-conjugated secondary antibody (1:2000 dilution) for 1 hour at room temperature

• Visualization: Develop with 3,3'-diaminobenzidine (DAB)

• Counterstaining: Use hematoxylin for nuclear visualization

• Quantification: Implement the modified H score system, where staining intensity (0-3) is multiplied by the percentage of positive tumor cells (0-100%) to generate scores ranging from 0-300

This validated protocol allows for semi-quantitative assessment of CPXM2 expression in clinical samples.

How can researchers effectively validate CPXM2 antibody specificity for their experimental systems?

Validating antibody specificity is crucial for generating reliable CPXM2 data. A comprehensive validation approach should include:

• Positive and negative control tissues/cells:

  • Use cell lines with known CPXM2 expression levels (gastric cancer or osteosarcoma cell lines as positive controls)

  • Include normal tissues with low expression as negative controls

• Knockout/knockdown validation:

  • Implement CPXM2 knockdown using validated shRNA sequences (e.g., AGGTTCATCGTGGCATTAA, ACGATGGAATTGACATCAA, TCCCAATATCACCAGAATT, or CTCAGTCCTGGTTTGATAA)

  • Compare antibody reactivity between wild-type and CPXM2-knockout samples

• Overexpression validation:

  • Use cells transfected with CPXM2 expression plasmids as positive controls

  • Confirm increased signal corresponding to CPXM2 molecular weight

• Multiple detection methods:

  • Cross-validate using Western blot, immunohistochemistry, and immunofluorescence

  • Ensure consistent detection patterns across methodologies

• Mass spectrometry confirmation:

  • For ultimate validation, immunoprecipitate the protein and confirm identity by mass spectrometry

This multi-layered approach ensures the antibody is specifically detecting CPXM2 rather than cross-reactive proteins.

What are the optimal approaches for quantifying CPXM2 expression in clinical samples?

For accurate quantification of CPXM2 in clinical samples, researchers should consider these methodological approaches:

• Immunohistochemistry quantification:

  • Implement the modified H score system for semi-quantitative assessment

  • Calculate scores by multiplying staining intensity (0-3) by percentage of positive cells (0-100%)

  • Categorize expression as high or low based on median H score of the cohort

  • Use digital pathology software for more objective quantification

• Western blot quantification:

  • Normalize CPXM2 expression to housekeeping proteins (GAPDH or β-actin)

  • Use densitometry software like ImageJ for band intensity quantification

  • Include standard curves with recombinant protein for absolute quantification

• RT-qPCR for mRNA expression:

  • Use validated primers (forward: 5′-GTGCGCGGGAAGAAATGAC-3′, reverse: 5′-CCTCCCTTGAGTGATGACACC-3′)

  • Normalize to stable reference genes like GAPDH

  • Calculate relative expression using the 2^−ΔΔCq method

• Database correlation:

  • Validate findings against public datasets from Oncomine, The Cancer Genome Atlas (TCGA), and Kaplan-Meier Plotter

These combined approaches provide robust quantification essential for correlating CPXM2 expression with clinical parameters and outcomes.

What strategies should be employed to resolve contradictory CPXM2 antibody results between different experimental platforms?

When facing contradictory results between different experimental platforms, consider implementing this systematic troubleshooting approach:

• Antibody epitope analysis:

  • Different antibodies may target distinct epitopes, affecting detection in certain conformations

  • Compare antibody epitope locations relative to protein domains and post-translational modifications

  • For Western blot discrepancies, consider whether native versus denatured conditions affect epitope accessibility

• Sample preparation differences:

  • Fixation methods for IHC may mask epitopes differently than protein extraction for Western blot

  • Extraction methods may differentially solubilize membrane-associated versus cytosolic CPXM2

  • Test multiple extraction protocols (RIPA versus NP-40 versus urea-based buffers)

• Cross-platform validation:

  • Perform parallel analysis with multiple antibodies across platforms

  • Supplement antibody-based methods with non-antibody approaches (mass spectrometry, RNA-seq)

  • Consider orthogonal validation using fluorescent protein tagging in cell models

• Cellular context consideration:

  • CPXM2 may exhibit different localization or processing in different cell types

  • Post-translational modifications may differ between cancer and normal tissues

  • Isoform expression may vary between experimental systems

• Methodological standardization:

  • Implement identical blocking conditions across platforms (5% milk in TBST)

  • Standardize antibody dilutions based on absolute concentration rather than ratios

  • Use recombinant CPXM2 as a positive control across all platforms

This systematic approach helps reconcile discrepancies and identify the most reliable detection methods for specific experimental contexts.

How does CPXM2 contribute to cancer progression and metastasis based on current evidence?

Evidence from multiple studies suggests CPXM2 plays a significant role in cancer progression through several mechanisms:

• Epithelial-mesenchymal transition (EMT) regulation:

  • CPXM2 expression modulates key EMT molecules

  • Western blotting has demonstrated that CPXM2 knockdown affects E-cadherin, N-cadherin, vimentin, and ZEB1 expression

  • Gene set enrichment analysis (GSEA) using RNA-seq data from TCGA showed that high CPXM2 expression positively correlates with EMT gene sets

• Cell proliferation effects:

  • Knockdown of CPXM2 in gastric cancer and osteosarcoma cells significantly impedes proliferation

  • CCK-8 assays have demonstrated reduced proliferation in CPXM2-silenced cells

  • Colony formation capacity is diminished following CPXM2 knockdown

• Migration and invasion promotion:

  • CPXM2 positively regulates cell migration in cancer cells

  • Scratch wound healing and Transwell® migration assays show decreased mobility in CPXM2-silenced cells

  • GSEA indicates correlation with HALLMARK_APICAL_JUNCTION gene sets, suggesting roles in cell-cell adhesion modulation

• Clinical correlation with metastasis:

  • CPXM2 overexpression associates with unfavorable prognosis regardless of Lauren classification and TNM staging in gastric cancer

  • Similar prognostic significance has been observed in osteosarcoma patients

These findings collectively suggest that CPXM2 promotes cancer aggressiveness primarily through EMT modulation, enhancing both proliferative and migratory capacities of cancer cells.

What are the recommended experimental designs for studying CPXM2 function in cancer models?

For robust investigation of CPXM2 function in cancer models, researchers should implement comprehensive experimental designs that include:

• Expression manipulation strategies:

  • Knockdown approaches: Use validated shRNA sequences (AGGTTCATCGTGGCATTAA, ACGATGGAATTGACATCAA, TCCCAATATCACCAGAATT, CTCAGTCCTGGTTTGATAA) delivered via lentiviral vectors

  • Overexpression systems: Transfect eukaryotic expression plasmids into appropriate cell models (e.g., normal cells, low-expressing cancer cells)

  • CRISPR-Cas9 knockout: For complete elimination of CPXM2 expression

• Functional assays for phenotypic assessment:

  • Proliferation: CCK-8 assay at 24, 48, 72, and 96 hours post-seeding with absorbance measurement at 450nm

  • Colony formation: Long-term (14-day) growth assays to assess clonogenic potential

  • Migration: Scratch wound healing assay with time-lapse imaging and Transwell® migration assay with 20% FBS as chemoattractant

  • Invasion: Matrigel-coated Transwell® systems to assess invasive capacity

• Molecular mechanism investigation:

  • Protein interaction studies: Co-immunoprecipitation to identify CPXM2 binding partners

  • Signaling pathway analysis: Western blotting for EMT markers (E-cadherin, N-cadherin, vimentin, ZEB1)

  • Transcriptional profiling: RNA-seq to identify global expression changes following CPXM2 manipulation

  • Pathway enrichment analysis: GSEA to identify affected pathways (e.g., HALLMARK_APICAL_JUNCTION, HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION)

• In vivo validation:

  • Xenograft models: Compare tumor growth between CPXM2-manipulated and control cells

  • Metastasis models: Tail vein injection or orthotopic implantation to assess metastatic potential

  • Patient-derived xenografts: For more clinically relevant models

This comprehensive approach enables thorough characterization of CPXM2's functional roles and underlying mechanisms in cancer progression.

How should researchers interpret CPXM2 expression patterns in heterogeneous clinical samples?

Interpreting CPXM2 expression in heterogeneous clinical samples requires careful consideration of multiple factors:

• Spatial heterogeneity considerations:

  • Implement tissue microarrays (TMAs) with multiple cores per tumor to account for intratumoral heterogeneity

  • Analyze both tumor center and invasive front, as CPXM2 may show differential expression related to EMT at invasion borders

  • Document expression in distinct tumor compartments (e.g., tumor cells, stroma, immune infiltrates)

• Integrated analytical approaches:

  • Combine IHC assessment with molecular profiling (RNA-seq, proteomics)

  • Use multiplexed immunofluorescence to simultaneously detect CPXM2 and EMT markers

  • Correlate with molecular subtypes (e.g., Lauren classification in gastric cancer)

• Quantification standardization:

  • Apply the modified H score system consistently (intensity 0-3 × percentage of positive cells)

  • Use digital pathology software for more objective quantification

  • Establish clear thresholds for high versus low expression based on median scores or ROC curve analysis

• Clinical correlation framework:

  • Stratify analysis by TNM stage, as CPXM2 prognostic significance may vary across stages

  • Assess correlation with specific metastatic patterns (e.g., lymphatic versus hematogenous)

  • Perform multivariate analysis to determine independent prognostic value

• Biological context integration:

  • Consider CPXM2 expression in the context of EMT signature genes

  • Analyze relationship to immune infiltration patterns

  • Evaluate association with treatment response biomarkers

This structured approach allows for more accurate interpretation of CPXM2 expression patterns and their clinical significance in heterogeneous tumor samples.

What are common technical issues with CPXM2 Western blotting and their solutions?

Researchers frequently encounter these technical challenges when performing Western blots for CPXM2:

Implementing these targeted solutions can significantly improve the reliability and reproducibility of CPXM2 Western blot experiments.

How can immunohistochemical detection of CPXM2 be optimized in challenging tissue types?

Optimizing CPXM2 immunohistochemistry in challenging tissues requires adaptations to standard protocols:

• For tissues with high background or autofluorescence:

  • Implement dual blocking with 10% normal serum followed by protein-based blockers

  • Use Sudan Black B (0.1-0.3%) to quench autofluorescence

  • Consider tyramide signal amplification for specific enhancement without increasing background

  • Test antigen retrieval variations (pH 6.0 citrate buffer has been validated)

• For poorly fixed or archival specimens:

  • Extend antigen retrieval time (15-20 minutes)

  • Test alternative retrieval methods (pressure cooking versus microwave)

  • Increase primary antibody concentration but reduce incubation temperature

  • Consider polymer-based detection systems for enhanced sensitivity

• For tissues with high endogenous peroxidase activity:

  • Implement dual peroxidase blocking (3% H₂O₂ in methanol for 10 minutes followed by commercial peroxidase block)

  • Use alternative detection systems (alkaline phosphatase instead of HRP)

  • Include additional washing steps before DAB development

• For tissues with complex extracellular matrix:

  • Pre-treat with hyaluronidase or other appropriate enzymes

  • Increase detergent concentration in washing buffers

  • Implement automated staining platforms for more consistent results

  • Consider post-fixation with glutaraldehyde to preserve tissue architecture

• Quantification in heterogeneous tissues:

  • Implement the validated H-score system with digital image analysis

  • Use multispectral imaging to distinguish true positivity from background

  • Incorporate machine learning algorithms for more objective assessment

These specialized approaches can significantly improve CPXM2 detection and quantification in challenging tissue contexts.

What controls are essential for validating CPXM2 antibody specificity in immunofluorescence applications?

For rigorous validation of CPXM2 antibody specificity in immunofluorescence applications, researchers should implement these essential controls:

• Primary antibody controls:

  • Positive control tissues/cells: Use samples with confirmed CPXM2 expression (gastric cancer or osteosarcoma cell lines)

  • Negative control tissues/cells: Include samples with minimal CPXM2 expression

  • Primary antibody omission: Replace primary antibody with antibody diluent

  • Isotype control: Use normal IgG from the same species at matching concentration

  • Concentration gradient: Test antibody at multiple dilutions to determine optimal signal-to-noise ratio

• Genetic manipulation controls:

  • Knockdown validation: Compare staining between scramble control and CPXM2 shRNA-transfected cells

  • Overexpression validation: Compare normal cells versus CPXM2-overexpressing cells

  • Peptide competition: Pre-absorb antibody with immunizing peptide prior to staining

• Technical controls:

  • Autofluorescence control: Examine unstained tissue sections through all filter sets

  • Secondary antibody control: Apply only secondary antibody without primary

  • Cross-reactivity control: Apply secondary antibody to sections stained with primary antibodies from different species

  • Nuclear counterstain: Include DAPI or similar dye for orientation and cell identification

• Multi-method validation:

  • Western blot correlation: Confirm that immunofluorescence signals correspond with Western blot results

  • Multi-antibody validation: Compare staining patterns with different antibodies against CPXM2

  • RNA-protein correlation: Compare immunofluorescence with in situ hybridization or RT-qPCR data

Implementation of these controls ensures that immunofluorescence signals accurately represent CPXM2 expression rather than technical artifacts or non-specific binding.

How can CPXM2 antibodies be utilized for co-localization studies with EMT markers?

For effective co-localization studies examining CPXM2 and EMT markers, researchers should implement these advanced methodological approaches:

• Multiplexed immunofluorescence strategy:

  • Use spectrally distinct fluorophores for CPXM2 and key EMT markers (E-cadherin, N-cadherin, vimentin, ZEB1)

  • Implement sequential staining protocols to avoid cross-reactivity between antibodies

  • Consider tyramide signal amplification for weaker signals

  • Use confocal microscopy with appropriate controls for spectral bleed-through

• Antibody selection and validation:

  • Choose CPXM2 antibodies raised in different species than EMT marker antibodies

  • Validate each antibody individually before multiplexing

  • Test multiple CPXM2 antibody clones to identify optimal performance in multiplexed settings

  • Perform single-stain controls for accurate computational unmixing

• Quantitative co-localization analysis:

  • Implement rigorous co-localization coefficients (Pearson's, Manders', etc.)

  • Use computational image analysis platforms (ImageJ with Coloc2, CellProfiler, etc.)

  • Establish thresholds based on control samples

  • Analyze subcellular compartment-specific co-localization

• Advanced imaging approaches:

  • Super-resolution microscopy (STORM, PALM) for nanoscale co-localization

  • Live-cell imaging with tagged proteins to examine dynamic interactions

  • 3D reconstruction from z-stacks to visualize spatial relationships

  • Proximity ligation assay (PLA) to detect close association (<40 nm)

• Biological validation of co-localization:

  • Correlate with co-immunoprecipitation data

  • Perform functional studies with domain-specific mutations

  • Use FRET or BRET approaches to confirm direct interactions

  • Validate in multiple cell types and patient samples

This comprehensive approach allows researchers to establish meaningful relationships between CPXM2 and EMT markers beyond simple co-expression.

What are the best practices for implementing CPXM2 immunoprecipitation to study protein interactions?

To successfully implement CPXM2 immunoprecipitation for protein interaction studies, follow these best practices:

• Optimized lysis conditions:

  • Use gentle lysis buffers to preserve protein-protein interactions

  • Test multiple buffers: NP-40 (0.5-1%), CHAPS (0.5%), or digitonin (0.5%) based buffers

  • Include phosphatase inhibitors and protease inhibitors to preserve modification states

  • Maintain cold temperature throughout extraction to prevent complex dissociation

• Antibody selection and validation:

  • Test multiple CPXM2 antibodies for immunoprecipitation efficiency

  • Validate antibody using Western blot to confirm specific CPXM2 capture

  • Consider epitope location relative to potential protein interaction domains

  • Use antibody crosslinking to Protein A/G beads to prevent antibody contamination in eluates

• Control implementation:

  • Input control: Save aliquot of pre-cleared lysate

  • Isotype control: Perform parallel IP with matched concentration of normal IgG

  • CPXM2-depleted control: Use lysate from CPXM2 knockdown cells

  • Reverse IP: Confirm interactions by immunoprecipitating suspected partner proteins

• Detection and analysis strategies:

  • Western blot for candidate interacting proteins (EMT regulators: E-cadherin, N-cadherin, vimentin, ZEB1)

  • Mass spectrometry for unbiased interactome analysis

  • Crosslinking prior to lysis for capturing transient interactions

  • Size exclusion chromatography to analyze native complexes

• Validation of biological relevance:

  • Confirm interactions in multiple cell types

  • Test interaction dependency on cellular conditions (e.g., EMT induction)

  • Perform domain mapping with truncated constructs

  • Correlate with functional outcomes in CPXM2 knockdown/overexpression models

These methodological considerations significantly enhance the quality and reliability of CPXM2 protein interaction studies.

How can researchers develop quantitative assays for measuring CPXM2 levels in patient samples for potential diagnostic applications?

Development of quantitative assays for CPXM2 measurement in patient samples requires methodological rigor for potential diagnostic applications:

• ELISA development strategy:

  • Select highly specific antibody pairs (capture and detection) targeting different CPXM2 epitopes

  • Optimize antibody concentrations, blocking buffers, and detection systems

  • Generate standard curves using recombinant CPXM2 protein

  • Validate with known positive (cancer) and negative (normal) samples

  • Determine analytical sensitivity, specificity, and reproducibility metrics

• Sample preparation optimization:

  • For tissue lysates: Standardize extraction protocols with RIPA buffer plus protease inhibitors

  • For serum/plasma: Evaluate need for pre-analytical steps (depletion of abundant proteins)

  • For FFPE samples: Optimize antigen retrieval conditions (citrate buffer pH 6.0)

  • Establish quality control metrics for sample adequacy

• Performance validation framework:

  • Analytical validation: precision (inter/intra-assay CV <10%), accuracy, linearity, LOD/LOQ

  • Clinical validation: sensitivity/specificity in differentiating cancer vs. normal tissues

  • Inter-laboratory reproducibility testing

  • Stability testing for clinical sample types

• Alternative platform considerations:

  • Automated IHC quantification using digital pathology and H-score system

  • Multiplex assays detecting CPXM2 alongside EMT markers

  • Mass spectrometry-based targeted proteomics (MRM/PRM)

  • Electrochemiluminescence immunoassay for enhanced sensitivity

• Clinical utility assessment:

  • Correlation with existing cancer staging systems (TNM)

  • Prognostic value determination through survival analysis

  • Evaluation as treatment response biomarker

  • Longitudinal monitoring feasibility assessment

This systematic approach to quantitative assay development provides the foundation for translating CPXM2 research findings into potential clinical diagnostic applications.